A Phase 1 interventional study of CTI-1601 and Placebo in Friedreich Ataxia, sponsored by Larimar Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-12.
Sponsored by Larimar Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.
Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 27th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2019, is one of 15 in phase 1, and was the 34th registered.
111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.
Browse Friedreich Ataxia studies →18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 16+ · Women only
Larimar Therapeutics, Inc. · Sites in United States
Ages 12–40
Scott Barbuto · Sites in United States
Lexeo Therapeutics · Sites in United States
Ages 6+
Solid Biosciences Inc. · Sites in United States
Ages 18–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 12
First in 2001; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is close to the median of 30 across 76 interventional studies indexed under Friedreich Ataxia.
Median enrollment 32 across the 49 interventional studies, 65 across the 21 observational. Of the 43 that completed or were terminated, 16 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 71 have an industry lead sponsor. The 10 most frequent:
Larimar Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Larimar Therapeutics, Inc. has 8 studies filed under Friedreich Ataxia — fewer than ten, so there is no comparison to draw.
6 of the studies in Friedreich Ataxia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953583Phase 3BiogenA Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia | 2027-11-16 |
| NCT06447025Larimar Therapeutics, Inc.An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | 2027-01 |
| NCT07869654Adjuvia Therapeutics, Inc.A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ATI-105 in Healthy Adults | 2027-05-27 |
| NCT07870590Graviton Bioscience CorporationGV101 for Friedreich's Ataxia (FA) Treatment | 2027-07 |
| NCT02316314Weill Medical College of Cornell UniversityCharacterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 71 studies in Friedreich Ataxia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia
Single Ascending Dose (SAD), Double-Blind, Placebo Controlled Study.
To evaluate the safety and tolerability of single ascending doses of CTI-1601 in subjects with Friedreich's ataxia.
Secondary Objectives:
CTI-1601 or Placebo - Dose/Mode of Administration: Single Dose/Subcutaneous
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CTI-1601
Biological: Placebo
CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Placebo Comparator
Number of Participants with Treatment-Emergent Adverse Events
Overall summary of the Participants with Treatment Emergent Adverse Events
Time frame: Through study completion, an average of 70 days
Number of Treatment Emergent Adverse Events by System Organ Classification and Preferred Term
Overall summary of Participants with Treatment Emergent Adverse Events by System Organ Classification (MedDRA version 22.0)
Time frame: Through study completion, an average of 70 days
Pharmacokinetics - Area under the concentration-time curve after a single dose
Summary assessment of changes in the area under the concentration-time curve after a single dose
Time frame: Up to 48 hours
Pharmacokinetics - Maximum observed plasma concentration after a single dose
Summary assessment of changes in the maximum observed plasma concentration after a single dose
Time frame: Up to 48 hours
Pharmacokinetics - Time to reach maximum plasma concentration after a single dose
Summary assessment of changes in time to reach maximum plasma concentration after a single dose
Time frame: Up to 48 hours
Pharmacokinetics - Area under the concentration-time curve from time 0 to infinity
Summary assessment of changes in the area under the concentration-time curve from time 0 to infinity
Time frame: 48 hours
Pharmacokinetics - Area under the concentration-time curve from time 0 to the last measurable time point
Summary assessment of changes in the Area under the concentration-time curve from time 0 to the last measurable time point
Time frame: 48 hours
Pharmacokinetics - Apparent total plasma clearance
Summary assessment of changes in the apparent total plasma clearance
Time frame: 48 hours
Pharmacokinetics - Terminal half-life estimation
Summary assessment of changes in the terminal half-life estimation
Time frame: 48 hours
Pharmacokinetics - Apparent volume of distribution
Summary assessment of changes in the apparent volume of distribution
Time frame: 48 hours
Changes from Baseline in Frataxin Levels in Buccal Cells
Summary assessment of changes in frataxin levels in buccal cells
Time frame: At baseline and up to 10 days
Changes from Baseline in Frataxin Levels in Whole Blood
Summary assessment of changes in frataxin levels in whole blood
Time frame: At baseline and up to 10 days
Changes in Gene Expression Profiling
Summary assessment of changes in gene expression levels
Time frame: At baseline and up to 10 days
Ran from Dec 2019 to primary completion in Oct 2020, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nomlabofusp
Larimar Therapeutics, Inc.